{"meshTagsMajor":["Molecular Targeted Therapy"],"meshTags":["Carcinoma, Non-Small-Cell Lung","Humans","Lung Neoplasms","Molecular Targeted Therapy","Practice Guidelines as Topic","Receptor Protein-Tyrosine Kinases","Receptor, Epidermal Growth Factor"],"meshMinor":["Carcinoma, Non-Small-Cell Lung","Humans","Lung Neoplasms","Practice Guidelines as Topic","Receptor Protein-Tyrosine Kinases","Receptor, Epidermal Growth Factor"],"genes":["EGFR gene","ALK gene","EGFR gene","ALK gene","EGFR","ALK"],"organisms":["9606"],"publicationTypes":["Journal Article"],"abstract":"Testing for EGFR gene mutations and ALK gene rearrangement is routinely used in advanced non-small-cell lung cancer for adequate patient selection to molecularly targeted therapies. We present Polish methodological recommendations for molecular analysis of EGFR and ALK genetic abnormalities. Recommendations specify clinical indications for testing, sample types and handling, as well as requirements for laboratories performing molecular diagnostics. ","title":"Methodological recommendations for the diagnostics of EGFR gene mutations and ALK gene rearrangement in the selection of non-small-cell lung cancer patients to molecularly targeted therapies.","pubmedId":"25133812"}